Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Globe Newswire•15/10/2026•07:00 ET
0
Key Highlights
- ➤Adlai Nortye partners with Lilly and Merck KGaA on AN4035 clinical trial
- ➤AN4035 Phase I evaluates monotherapy and cetuximab combination in RAS-addicted solid tumors
- ➤Lilly supplies cetuximab at no cost for U.S. trial sites
- ➤Merck KGaA supplies cetuximab at no cost for Australia and China sites
Expert Statements
Dr. Archie Tse, President, Head of Research & Development at Adlai Nortye
“We are pleased to enter clinical trial collaborations with both Lilly and Merck KGaA, Darmstadt, Germany to explore cetuximab in combination with AN4035, our first-in-class investigational ADC targeting CEACAM5 and armed with a highly potent pan-RAS(ON) inhibitor payload.”
Dr. Archie Tse, President, Head of Research & Development at Adlai Nortye
“Dual inhibition of EGFR and RAS signaling is a compelling strategy for treating RAS-addicted cancers, but overlapping toxicities may limit systemic combinations.”
Dr. Archie Tse, President, Head of Research & Development at Adlai Nortye
“By selectively delivering a potent pan-RAS(ON) inhibitor to CEACAM5-expressing tumors through an ADC, AN4035 may broaden the therapeutic window for this rational combination with cetuximab.”
Dr. Archie Tse, President, Head of Research & Development at Adlai Nortye
“We are excited to evaluate this approach with participation by Lilly and Merck KGaA, Darmstadt, Germany in these patients with high unmet need.”
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial
Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites
Get started
Create a free account to read the full story.